サンプル依頼リスト カート
  • English
  • Korean
表紙：がん治療向けバイオ医薬品の世界市場規模調査＆予測：製品別、用途別、流通チャネル別、地域別分析、2023-2030年
市場調査レポート
商品コード
1303546

がん治療向けバイオ医薬品の世界市場規模調査＆予測：製品別、用途別、流通チャネル別、地域別分析、2023-2030年

Global Cancer Biologics Market Size study & Forecast, by Product, by Application, by Distribution Channel and Regional Analysis, 2023-2030

出版日
ページ情報
英文
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
がん治療向けバイオ医薬品の世界市場規模調査＆予測：製品別、用途別、流通チャネル別、地域別分析、2023-2030年
出版日: 2023年07月01日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん治療向けバイオ医薬品とは、がん細胞の増殖や転移に関与する特定の分子や経路を標的とするように設計された薬剤の一群を指します。

バイオ医薬品は通常、タンパク質、抗体、ワクチンなどの生物に由来し、がん細胞上の特定の標的と相互作用するように設計されています。これらの医薬品は様々な種類のがんの治療に用いられることが多く、単独で、あるいは化学療法、放射線療法、手術などの他の治療と組み合わせて用いられます。がん治療向けバイオ医薬品は、生物学的療法、生物療法、標的療法とも呼ばれます。世界のがん治療向けバイオ医薬品市場の主な促進要因は、がん罹患率の増加と、標的医療および個別化医療に対する需要の増加です。さらに、技術の進歩と良好な規制環境が、予測期間2023-2030年にかけて市場に有利な成長機会を生み出しています。

がんの罹患率の上昇は、がん治療向けバイオ医薬品市場の主要促進要因の1つです。GLOBOCAN 2020の統計によると、2020年の世界全体での新規がん患者数は1,930万人でした。この数は2040年までに3,020万人に増加すると予想されています。このがん患者の大幅な増加は、さまざまな種類のがんの治療で有望視されている低分子医薬品を含む、効果的ながん治療の緊急の必要性を強調しています。しかし、がん治療向けバイオ医薬品はコストが高いため、2023-2030年の予測期間を通じて市場の成長が阻害されます。

がん治療向けバイオ医薬品の世界市場調査において考慮された主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。がん治療向けバイオ医薬品の北米市場は、大手製薬会社の存在、高い医療支出、がん有病率の増加により、最大市場になると予想されます。米国は先進的ながん治療の採用率が高いため、市場を独占すると予想されます。アジア太平洋地域のがん治療向けバイオ医薬品市場は、がん罹患率の増加、医療インフラの改善、研究開発投資の増加などの要因により、大きな成長が見込まれます。中国と日本が市場成長に大きく貢献すると予想されます。

本調査の目的は、近年のさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

  • 市場スナップショット
  • 世界市場・セグメント別市場推計・予測、2020-2030年
    • がん治療向けバイオ医薬品市場：地域別、2020～2030年
    • がん治療向けバイオ医薬品市場：製品別、2020～2030年
    • がん治療向けバイオ医薬品市場：用途別、2020～2030年
    • がん治療向けバイオ医薬品市場：流通チャネル別、2020～2030年
  • 主要動向
  • 調査手法
  • 調査前提条件

第2章 がん治療向けバイオ医薬品の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 世界のがん治療向けバイオ医薬品市場力学

  • がん治療向けバイオ医薬品市場の影響分析（2020年～2030年）
    • 市場促進要因
      • がん罹患率の増加
      • 標的医療と個別化医療に対する需要の増加
    • 市場の課題
      • がん治療向けバイオ医薬品の高コスト
    • 市場機会
      • 技術の進歩
      • 有利な規制環境

第4章 がん治療向けバイオ医薬品の世界市場の産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 がん治療向けバイオ医薬品の世界市場：製品別

  • 市場スナップショット
  • がん治療向けバイオ医薬品の世界市場：製品別、業績、潜在能力分析
  • がん治療向けバイオ医薬品の世界市場：製品別推定・予測、2020-2030年
  • がん治療向けバイオ医薬品市場、サブセグメント別分析
    • モノクローナル抗体
    • サイトカインベース免疫療法
    • がんワクチン
    • CAR-T細胞療法
    • 免疫チェックポイント阻害薬

第6章 がん治療向けバイオ医薬品の世界市場：用途別

  • 市場スナップショット
  • がん治療向けバイオ医薬品の世界市場：用途別、業績-潜在能力分析
  • がん治療向けバイオ医薬品の世界市場：用途別推定・予測、2020～2030年
  • がん治療向けバイオ医薬品市場、サブセグメント分析
    • 非小細胞肺がん
    • 前立腺がん
    • 乳がん
    • 急性骨髄性白血病
    • リンパ腫
    • その他

第7章 がん治療向けバイオ医薬品の世界市場：流通チャネル別

  • 市場スナップショット
  • がん治療向けバイオ医薬品の世界市場：流通チャネル別、業績-潜在能力分析
  • がん治療向けバイオ医薬品の世界市場、流通チャネル別推定・予測、2020～2030年
  • がん治療向けバイオ医薬品市場、サブセグメント分析
    • 病院
    • クリニック
    • その他

第8章 がん治療向けバイオ医薬品の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • がん治療向けバイオ医薬品市場、地域別市場スナップショット
  • 北米
    • 米国
      • 製品の推定・予測、2020-2030年
      • 用途別推定・予測、2020-2030年
      • 流通チャネルの推定・予測、2020-2030年
    • カナダ
  • 欧州のがん治療向けバイオ医薬品市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋のがん治療向けバイオ医薬品市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカのがん治療向けバイオ医薬品市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第9章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Roche Holding AG
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
      • 最近の動向
    • Novartis AG
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Amgen Inc.
    • Johnson & Johnson
    • Pfizer Inc.
    • AstraZeneca plc
    • Eli Lilly and Company
    • AbbVie Inc.

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Cancer Biologics Market, report scope
  • TABLE 2. Global Cancer Biologics Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Cancer Biologics Market estimates & forecasts by Product 2020-2030 (USD Billion)
  • TABLE 4. Global Cancer Biologics Market estimates & forecasts by Application 2020-2030 (USD Billion)
  • TABLE 5. Global Cancer Biologics Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)
  • TABLE 6. Global Cancer Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Cancer Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Cancer Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Cancer Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Cancer Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Cancer Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Cancer Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Cancer Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Cancer Biologics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Cancer Biologics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. U.S. Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. Canada Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. Canada Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. UK Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. UK Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. Germany Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. Germany Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. France Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. France Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. Italy Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Italy Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Spain Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Spain Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. RoE Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. RoE Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. China Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. China Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. India Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. India Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. Japan Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. Japan Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. South Korea Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. South Korea Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. Australia Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. Australia Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. Brazil Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Brazil Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Mexico Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Mexico Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. RoLA Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. RoLA Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. Saudi Arabia Cancer Biologics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. South Africa Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoMEA Cancer Biologics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Cancer Biologics Market
  • TABLE 71. List of primary sources, used in the study of global Cancer Biologics Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Cancer Biologics Market, research methodology
  • FIG 2. Global Cancer Biologics Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Cancer Biologics Market, key trends 2022
  • FIG 5. Global Cancer Biologics Market, growth prospects 2023-2030
  • FIG 6. Global Cancer Biologics Market, porters 5 force model
  • FIG 7. Global Cancer Biologics Market, pest analysis
  • FIG 8. Global Cancer Biologics Market, value chain analysis
  • FIG 9. Global Cancer Biologics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Cancer Biologics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Cancer Biologics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Cancer Biologics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Cancer Biologics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Cancer Biologics Market, regional snapshot 2020 & 2030
  • FIG 15. North America Cancer Biologics Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Cancer Biologics Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia Pacific Cancer Biologics Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Cancer Biologics Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Cancer Biologics Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Cancer Biologics Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Cancer biologics refer to a class of drugs that are designed to target specific molecules or pathways involved in the growth and spread of cancer cells. They are typically derived from living organisms, such as proteins, antibodies, and vaccines, and are designed to interact with specific targets on cancer cells. These drugs are often used in the treatment of various types of cancer and may be used alone or in combination with other treatments, such as chemotherapy, radiation therapy, or surgery. Cancer biologics may also be referred to as biologic therapies, biotherapeutics, or targeted therapies. The major driving factors for the Global Cancer Biologics Market are increasing incidences of cancer and increasing demand for targeted and personalized medicine. Moreover, technological advancements and favorable regulatory environment are creating lucrative growth opportunities in the market over the forecast period 2023-2030.

The rising incidences of cancer are one of the primary drivers of the cancer biologics market. Globally, the number of new cases of cancer was 19.3 million in 2020, according to the GLOBOCAN 2020 statistics. This number is expected to increase to 30.2 million by 2040. This significant rise in cancer cases underscores the urgent need for effective cancer treatments, including small molecule drugs, which have shown promise in the treatment of various types of cancer. However, the high cost of Cancer Biologics stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Cancer Biologics Market study include: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. The North American market for cancer biologics is expected to be the largest due to the presence of major pharmaceutical companies, high healthcare expenditure, and increasing cancer prevalence. The US is expected to dominate the market due to the high adoption rate of advanced cancer treatments. The Asia-Pacific market for cancer biologics is expected to witness significant growth due to factors such as increasing cancer prevalence, improving healthcare infrastructure, and increasing investment in R&D. China and Japan are expected to be the major contributors to the market growth.

Major market players included in this report are:

  • Roche Holding AG
  • Novartis AG
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • AbbVie Inc.

Recent Developments in the Market:

  • In January 2020, F. Hoffmann-La Roche AG announced that it had submitted a supplemental biological license application to the U.S. Food and Drug Administration (FDA) for Tecentriq (atezolizumab), in combination with the drug Avastin (bevacizumab), for the treatment of the most common form of liver cancer.

Global Cancer Biologics Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Product, Application, Distribution Channel, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Product:

  • Monoclonal Antibodies
  • Cytokine-Based Immunotherapy
  • Cancer Vaccines
  • CAR-T Cell Therapy
  • Immune Checkpoint Inhibitors

By Application:

  • Non-small Cell Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Acute Myeloid Leukemia
  • Lymphoma
  • Others

By Distribution Channel:

  • Hospitals
  • Clinics
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Cancer Biologics Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Cancer Biologics Market, by Product, 2020-2030 (USD Billion)
    • 1.2.3. Cancer Biologics Market, by Application, 2020-2030 (USD Billion)
    • 1.2.4. Cancer Biologics Market, by Distribution Channel, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Cancer Biologics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Cancer Biologics Market Dynamics

  • 3.1. Cancer Biologics Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing Incidence of cancer
      • 3.1.1.2. Increasing demand for targeted and personalized medicine
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Cancer Biologics
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Technological advancements
      • 3.1.3.2. Favorable regulatory environment

Chapter 4. Global Cancer Biologics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Cancer Biologics Market, by Product

  • 5.1. Market Snapshot
  • 5.2. Global Cancer Biologics Market by Product, Performance - Potential Analysis
  • 5.3. Global Cancer Biologics Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
  • 5.4. Cancer Biologics Market, Sub Segment Analysis
    • 5.4.1. Monoclonal Antibodies
    • 5.4.2. Cytokine-Based Immunotherapy
    • 5.4.3. Cancer Vaccines
    • 5.4.4. CAR-T Cell Therapy
    • 5.4.5. Immune Checkpoint Inhibitors

Chapter 6. Global Cancer Biologics Market, by Application

  • 6.1. Market Snapshot
  • 6.2. Global Cancer Biologics Market by Application, Performance - Potential Analysis
  • 6.3. Global Cancer Biologics Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
  • 6.4. Cancer Biologics Market, Sub Segment Analysis
    • 6.4.1. Non-small Cell Lung Cancer
    • 6.4.2. Prostate Cancer
    • 6.4.3. Breast Cancer
    • 6.4.4. Acute Myeloid Leukemia
    • 6.4.5. Lymphoma
    • 6.4.6. Others

Chapter 7. Global Cancer Biologics Market, by Distribution Channel

  • 7.1. Market Snapshot
  • 7.2. Global Cancer Biologics Market by Distribution Channel, Performance - Potential Analysis
  • 7.3. Global Cancer Biologics Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
  • 7.4. Cancer Biologics Market, Sub Segment Analysis
    • 7.4.1. Hospitals
    • 7.4.2. Clinics
    • 7.4.3. Others

Chapter 8. Global Cancer Biologics Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Cancer Biologics Market, Regional Market Snapshot
  • 8.4. North America Cancer Biologics Market
    • 8.4.1. U.S. Cancer Biologics Market
      • 8.4.1.1. Product breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. Distribution Channel breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Cancer Biologics Market
  • 8.5. Europe Cancer Biologics Market Snapshot
    • 8.5.1. U.K. Cancer Biologics Market
    • 8.5.2. Germany Cancer Biologics Market
    • 8.5.3. France Cancer Biologics Market
    • 8.5.4. Spain Cancer Biologics Market
    • 8.5.5. Italy Cancer Biologics Market
    • 8.5.6. Rest of Europe Cancer Biologics Market
  • 8.6. Asia-Pacific Cancer Biologics Market Snapshot
    • 8.6.1. China Cancer Biologics Market
    • 8.6.2. India Cancer Biologics Market
    • 8.6.3. Japan Cancer Biologics Market
    • 8.6.4. Australia Cancer Biologics Market
    • 8.6.5. South Korea Cancer Biologics Market
    • 8.6.6. Rest of Asia Pacific Cancer Biologics Market
  • 8.7. Latin America Cancer Biologics Market Snapshot
    • 8.7.1. Brazil Cancer Biologics Market
    • 8.7.2. Mexico Cancer Biologics Market
  • 8.8. Middle East & Africa Cancer Biologics Market
    • 8.8.1. Saudi Arabia Cancer Biologics Market
    • 8.8.2. South Africa Cancer Biologics Market
    • 8.8.3. Rest of Middle East & Africa Cancer Biologics Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Roche Holding AG
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Novartis AG
    • 9.3.3. Merck & Co., Inc.
    • 9.3.4. Bristol-Myers Squibb Company
    • 9.3.5. Amgen Inc.
    • 9.3.6. Johnson & Johnson
    • 9.3.7. Pfizer Inc.
    • 9.3.8. AstraZeneca plc
    • 9.3.9. Eli Lilly and Company
    • 9.3.10. AbbVie Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption